DDrare: Database of Drug Development for Rare Diseases

Searched query = "Cryopyrin-associated periodic syndrome", "Cryopyrin associated periodic fever syndrome", "Familial cold autoinflammatory syndrome", "FCAS", "Mucke-Wells syndrome", "MWS", "Chronic infantile neurologic cutaneous, and articular syndrome", "CINCA syndrome", "Neonatal onset multisystem inflammatory disease", "NOMID"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = ACZ885; ACZ885 drug substance; ATI-450; Anakinra; Anti-interleukin-1B monoclonal antibody; C-028380; CANAKINUMAB; Canakinumab; Canakinumab (ACZ885); Canakinumab (WHO approval pending); Canakinumab (company code: ACZ885D); ILARIS; IZD174; IZD334; Ilaris; Inzomelid; Kineret; Recombinant human monoclonal antibody to human IL-1Beta of the IgG1/K class; Recombinant human monoclonal antibody to human IL-1beta of the IgG1/K class; Rilonacept; Rilonacept 160 mg; Tranilast; XOMA 052

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2007-004367-22-IT (EUCTR)	14/03/2008	07/05/2008	An open-label, long-term safety and efficacy study of ACZ885 (anti-interleukin-1β monoclonal antibody) administered for at least 6 months in patients with the following cryopyrin-associated periodic syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Muckle-Wells Syndrome with overlapping symptoms of Neonatal Onset Multisystem Inflammatory Disease - ND	An open-label, long-term safety and efficacy study of ACZ885 (anti-interleukin-1β monoclonal antibody) administered for at least 6 months in patients with the following cryopyrin-associated periodic syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Muckle-Wells Syndrome with overlapping symptoms of Neonatal Onset Multisystem Inflammatory Disease - ND	Muckle-Wells Syndrome, Familial Cold autoinflammatory syndrome MedDRA version: 9.1;Level: LLT;Classification code 10064569;Term: Muckle-Wells syndrome	Product Name: anti-interleukin-1B monoclonal antibody Product Code: ACZ885 INN or Proposed INN: anti-interleukin-1B monoclonal antibody	NOVARTIS FARMA	NULL	Not Recruiting			Female: yes Male: yes	80		Germany;United Kingdom;France;Spain;Italy

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

EUCTR2007-004367-22-IT
(EUCTR)

14/03/2008

07/05/2008

An open-label, long-term safety and efficacy study of ACZ885 (anti-interleukin-1β monoclonal antibody) administered for at least 6 months in patients with the following cryopyrin-associated periodic syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Muckle-Wells Syndrome with overlapping symptoms of Neonatal Onset Multisystem Inflammatory Disease - ND

Muckle-Wells Syndrome, Familial Cold autoinflammatory syndrome
MedDRA version: 9.1;Level: LLT;Classification code 10064569;Term: Muckle-Wells syndrome

Product Name: anti-interleukin-1B monoclonal antibody
Product Code: ACZ885
INN or Proposed INN: anti-interleukin-1B monoclonal antibody

NOVARTIS FARMA

NULL

Not Recruiting

Female: yes
Male: yes

Germany;United Kingdom;France;Spain;Italy